Justin Cooper , 2025-05-12 18:03:00
SALT LAKE CITY — In this Healio Video Perspective from the ARVO meeting, Patrick Johnson, PhD, president of Sydnexis, shares data on myopia progression that is representative of children in the U.S.
“In a representative population of the U.S. — not an exclusively Asian population, but a population that encompasses about 20% Asians — we see a slightly lower rate of progression than you see in other studies,” Johnson said. “But what’s really interesting is we see that 13 and 14 years old is approximately the age where myopia progression slows down and comes to a crawl.”
The data come from the phase 3 STAR study of SYD-101 (atropine sulfate ophthalmic solution 0.01% and 0.03%, Sydnexis) for the treatment of myopia progression in children. The study is the “world’s largest study for the treatment of pediatric progressive myopia ever conducted,” Johnson said.
“The FDA is always interested in a very representative population, and that’s what we gave them,” he added.
Reference:
- Cheetham JK, et al. The natural history of myopia progression in a large diverse pediatric population. Presented at: Association for Research in Vision and Ophthalmology meeting; May 4-8, 2025; Salt Lake City.
Sources/Disclosures
Collapse
Johnson P, et al. Methods and baseline data from the STAR study: A phase 3 multicenter trial of SYD-101 for myopia progression in 800+ children. Presented at: Association for Research in Vision and Ophthalmology meeting; May 4-8, 2025; Salt Lake City.
Disclosures:
Johnson reports being president of Sydnexis.
